Expansion of the APIS Breast Cancer Portfolio🎗️
ESR1 dPCR Kit and PIK3CA qPCR Kit
Join us at ABP BDIAP 2024
23 November
London, UK
Bioinformatics Services & Software Capabilities
Integrating AI and ML in in silico research
APIS goes to AMP 2024
19 - 23 November
Vancouver, Canada
Introducing APIS Assay Technologies
APIS Assay Technologies designs, manufactures, and sells innovative Drug-Linked biomarker assays that improve patient outcomes across a wide range of disease areas
APIS has a strong focus in oncogenomics and pharmacogenomics (PGx) and leverages systems biology, interrogation of multi-OMICs biodata, and deployment of innovative ‘Clickmer’ ligand binding technology, to translate Drug-Linked biomarkers into clinical utility
APIS has deep expertise and capabilities in IVD development of molecular & immuno-assays for ultimate product realisation as diagnostic tests.
Our Mission
To leverage our expertise in the design, development, and supply of diagnostic assays, therapeutic solutions, and bioinformatics. To enable faster, accurate prediction and prevention of disease, driven by the ambition to improve human health.
Our Vision
More Solutions, to more people to improve and save lives.
Oncology Product Portfolio
Innovative Solutions for Oncology; Advanced Assays with Precise Results.
Breast Cancer Subtyping Kit is a RT-qPCR assay for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers
ESR1 Mutations Kit is a qPCR assay for the precise detection of 11 key mutations within the oestrogen receptor gene
ESR1 dPCR Kit is a dPCR assay detecting 11 key mutations within the oestrogen receptor gene
PIK3CA qPCR Kit is a qPCR assay for detection of the 5 most prevalent mutations in the PIK3CA gene
MET Alterations Kit is a RT-qPCR assay detecting both MET exon 14 skipping mutation and MET gene overexpression
Contract IVD Development
The Contract Development activity operates as a distinct commercial service line, with focus on the tailored development of novel molecular diagnostic tests on medical diagnostic platforms.
Bioinformatics and Software Development
Bioinformatics is an interdisciplinary field of science that combines biology, computer science, information engineering, mathematics, and statistics.
The primary goal of bioinformatics is the in-silico analysis and interpretation of higher-order biological data by applying existing, and/or developing novel mathematical methods and software tools.
Clickmer Systems
Synthetic antibody analogues known as Clickmers are chemically modified ssDNA oligonucleotides that, based on their sequence and modifications, form three-dimensional structures that adaptively bind to their target molecules with high affinity and specificity.